Corrigendum to: Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebocontrolled trial (Int J Clin Pract., (2016), 70, 4, (302-311), 10.1111/ijcp.12790);Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: A multi-centre, randomised, double-blinded, placebo-controlled trial

International Journal of Clinical Practice

Volumn 70, Issue 4, 2016, Pages 302-311

  Oh, B ^a   Choi, W S ^b   Park, S B ^c   Cho, B ^d   Yang, Y J ^e   Lee, E S ^e   Lee, J H ^e  

^a Seoul National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Ajou University Medical Center   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Inje University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID COMPOSITE; URSODEOXYCHOLIC ACID DERIVATIVE; CHOLAGOGUE; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHECKLIST INDIVIDUAL STRENGTH SCORE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FATIGUE; FATTY LIVER; FEMALE; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOTIVATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; LIVER; LIVER FUNCTION TEST; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDY;

ADULT; CHOLAGOGUES AND CHOLERETICS; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84962393995     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12930     Document Type: Erratum

References (31)

1. Krupp LB, Pollina DA,. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 1996; 9: 456-60.
2. Berrios GE,. Feelings of fatigue and psychopathology: a conceptual history. Compr Psychiatry 1990; 31: 140-51.
3. Norheim KB, Jonsson G, Omdal R,. Biological mechanisms of chronic fatigue. Rheumatology 2011; 50: 1009-18.
4. Copaci I, Micu L, Iliescu L, Voiculescu M,. New therapeutical indications of ursodeoxycholic acid. Rom J Gastroenterol 2005; 14: 259-66.
5. Saksena S, Tandon RK,. Ursodeoxycholic acid in the treatment of liver diseases. Postgrad Med J 1997; 73: 75-80.
6. Sato S, Miyake T, Tobita H, et al., A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients. World J Gastroenterol 2009; 15: 2782-6.
7. Xiang Z, Chen YP, Ma KF, et al., The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol 2013; 13: 140.
8. Buryova H, Chalupsky K, Zbodakova O, et al., Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity. BMC Gastroenterol 2013; 13: 155.
9. Ikegami T, Matsuzaki Y,. Ursodeoxycholic acid: mechanism of action and novel clinical applications. Hepatol Res 2008; 38: 123-31.
10. Woollett LA, Buckley DD, Yao L, et al., Effect of ursodeoxycholic acid on cholesterol absorption and metabolism in humans. J Lipid Res 2003; 44: 935-42.
11. Nakagawasai O, Yamada K, Nemoto W, et al., Liver hydrolysate assists in the recovery from physical fatigue in a mouse model. J Pharmacol Sci 2013; 123: 328-35.
12. Bultmann U, de Vries M, Beurskens AJ, et al., Measurement of prolonged fatigue in the working population: determination of a cutoff point for the checklist individual strength. J Occup Health Psychol 2000; 5: 411-6.
13. Lee KK, Choi WS, Yum KS, et al., Efficacy and safety of human placental extract solution on fatigue: a double-blind, randomized, placebo-controlled study. Evid Based Complement Alternat Med 2012; 2012: 130875.
14. Day CP,. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med 2006; 6: 19-25.
15. Marchesini G, Marzocchi R, Agostini F, Bugianesi E,. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16: 421-7.
16. Skelly MM, James PD, Ryder SD,. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001; 35: 195-9.
17. Poupon R, Chretien Y, Poupon RE, et al., Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1: 834-6.
18. Leuschner U, Fischer H, Kurtz W, et al., Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97: 1268-74.
19. Poupon RE, Balkau B, Eschwege E, Poupon R,. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324: 1548-54.
20. Poupon RE, Poupon R, Balkau B,. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994; 330: 1342-7.
21. Pares A, Caballeria L, Rodes J, et al., Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000; 32: 561-6.
22. EASL Clinical Practice Guidelines. Management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.
23. Grahame Hardie D,. AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J Int Med 2014; 276: 543-59.
24. Viollet B, Guigas B, Leclerc J, et al., AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol 2009; 196: 81-98.
25. Amaral JD, Viana RJ, Ramalho RM, et al., Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 2009; 50: 1721-34.
26. Kennedy G, Spence VA, McLaren M, et al., Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med 2005; 39: 584-9.
27. Maes M, Twisk FN,. Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. BMC Med 2010; 8: 35.
28. Stulemeijer M, de Jong LW, Fiselier TJ, et al., Cognitive behaviour therapy for adolescents with chronic fatigue syndrome: randomised controlled trial. BMJ 2005; 330: 14.
29. Shahid A, Shen J, Shapiro CM,. Measurements of sleepiness and fatigue. J Psychosom Res 2010; 69: 81-9.
30. Kim YK, Cha NH,. Correlations among occupational stress, fatigue, and depression in call center employees in Seoul. J Phys Ther Sci 2015; 27: 3191-4.
31. Park JS, Choi ER,. A study on relationships between sleep disorder, fatigue and job stress in police shift-workers. Police Sci J 2010; 5 (1): 25-53.